Timolol treatment after myocardial infarction in diabetic patients.
In diabetic patients long-term treatment with timolol after myocardial infarction was related to a reduction in overall mortality, total cardiac death, sudden death, and nonfatal reinfarction, compared with patients in a placebo group. The analyses were based on 99 diabetic patients in the Norwegian timolol multicenter study. The dosage of timolol was 10 mg twice daily and the follow-up period was 12-33 mo (mean: 17 mo). When analyzing all randomized patients, there were 14 deaths in the placebo group and 6 deaths in the timolol group, a reduction of 62.8% (P less than 0.05). The number of nonfatal reinfarctions was 10 in the placebo group and 2 in the timolol group, a reduction of 82.7% (P less than 0.05). With regard to inclusion rate, side effects, withdrawals, and timolol-related reduction in mortality and reinfarction, the diabetic patients basically behaved like nondiabetic patients. The data were analyzed retrospectively and should be confirmed by a prospective study. The study also indicates that long-term treatment with timolol may induce slight carbohydrate intolerance.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003645:Death, Sudden / Q000453:epidemiology; D048909:Diabetes Complications; D003925:Diabetic Angiopathies / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality; D010919:Placebos; D011412:Propanolamines / Q000008:administration & dosage*; D011897:Random Allocation; D012008:Recurrence; D013997:Time Factors; D013999:Timolol / Q000008:administration & dosage*
D010919:Placebos; D011412:Propanolamines; D013999:Timolol